Spherical Nucleic Acids (SNAs) as Potent Gene Regulation and ImmunoModulatory Agents

David  Giljohann

David Giljohann

CEO

AuraSense

Dr. Giljohann received his BA and Ph.D. degrees from Northwestern University (2003, 2009) and currently holds an appointment as a Postdoctoral Fellow at the International Institute of Nanotechnology. Dr. Giljohann completed his Ph.D. in the laboratory of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlares and antisense DNA and siRNA gold nanoparticles. Dr. Giljohann has been collaborating extensively with physicians in the clinical setting to translate these technologies into impactful materials to improve human health. Dr. Giljohann has been recognized for his work with a Materials Research Society Gold Award, Baxter Innovation Award, Rappaport Award for Research Excellence, NSEC Outstanding Research Award, and as a finalist in the National Inventors Hall of Fame Collegiate Inventors Competition. He has contributed to over 25 manuscripts and over 100 patents and applications. In his role at AuraSense, Dr. Giljohann is leading scientific partnerships efforts to move AuraSense technologies to commercialization.

Sponsor & Exhibitor Opportunities

 Exhibit and Showcase
 Become a Sponsor

Please contact: Denise Lee


TechConnect Acceleration Partners:

BASF
Bosch
Corning
Dupont
Jabil
Lockheed Martin
LORD
MWV
momentive
nationalgrid
SAINT-GOBAIN
Sabic
SKInnovation

In Partnership with

NSTI


Sponsorship Opportunities: Contact Denise Lee

Free Subscription

E-mail:

pbh(); ?>